Lunit and Summit Test AI Pathology for Ivonescimab Research

Oct 24, 2026
Lunit and Summit Therapeutics will use the Lunit SCOPE IO pathology platform to analyze tumor tissue images for research involving ivonescimab.

Lunit and Summit Therapeutics announced a research agreement to evaluate Lunit SCOPE IO for tumor microenvironment analysis in Summit's ivonescimab programs. The companies will apply the AI pathology platform to hematoxylin and eosin stained whole slide images.

The research will examine whether the platform can identify quantitative and spatial features related to tumor cells, immune activity and surrounding tissue. The companies plan to explore its use in biomarker discovery, patient selection and analysis of treatment response.

Ivonescimab is an investigational bispecific antibody that targets PD-1 and VEGF. Lunit says its SCOPE products are for research use only. The companies did not report clinical outcome data with the agreement.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.